Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akoya Biosciences Inc (NQ: AKYA )

3.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.900
Bid (Size) 3.650 (1)
Ask (Size) 6.240 (2)
Prev. Close 3.900
Today's Range 3.900 - 3.900
52wk Range 3.040 - 8.800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
From Akoya Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-18.41%
-18.41%
1 Month
-20.73%
-20.73%
3 Month
-22.92%
-22.92%
6 Month
+9.86%
+9.86%
1 Year
-45.30%
-45.30%

More News

Read More
AKYA Stock Earnings: Akoya Biosciences Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Recap: Akoya Biosciences Q4 Earnings
Via Benzinga
Earnings Outlook For Akoya Biosciences
Via Benzinga
Analyst Ratings for Akoya Biosciences
Via Benzinga
Expert Ratings for Akoya Biosciences
Via Benzinga
Recap: Akoya Biosciences Q3 Earnings
Via Benzinga
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
From Akoya Biosciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 4, 2024
Via Benzinga
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Where Akoya Biosciences Stands With Analysts
Via Benzinga
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Participate at 42nd Annual J.P. Morgan Healthcare Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Participate at Three Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.